Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 50
Filtrar
1.
Br J Nutr ; 127(6): 862-871, 2022 03 28.
Artigo em Inglês | MEDLINE | ID: mdl-33971993

RESUMO

The consumption of nuts and extra-virgin olive oil has been associated with suppression of inflammatory pathways that contribute to atherosclerosis, but its role on the modulation of the inflammatory profile in patients with established coronary artery disease (CAD) is unclear. The aim of this study was to evaluate the effects of adding pecan nuts or extra-virgin olive oil to a healthy diet on inflammatory markers in patients with stable CAD. In this randomised clinical trial, 204 patients were enrolled to three study groups: sixty seven to control group (CG: healthy diet), sixty eight to pecan nuts group (PNG: 30 g/d of pecans + healthy diet) and sixty nine to extra-virgin olive oil group (OOG: 30 ml/d of extra-virgin olive oil + healthy diet). High-sensitivity C-reactive protein (hs-CRP, in mg/l), fibrinogen (mg/dl), IL 2, 4, 6, 10 (pg/ml) and interferon-γ (IFN-γ, in pg/ml), IL-6/IL-10, IL-2/IL-4 and IFN-/γIL-4 ratios were evaluated at baseline and after the follow-up (12 weeks). As main results, after adjustment for sex, statin used and relative body weight variation, there were no differences between groups regarding inflammatory markers at the end of the study. IL-6 levels (primary outcome) were reduced in 12 weeks when compared with baseline in all study groups (CG: difference: -0·593 (se = 0·159) pg/dL; PNG: difference: -0·335 (se = 0·143) pg/dl; OOG: IL-6 difference: -0·325 (se = 0·143) pg/dl). In conclusion, there was no significant effect of including pecan nuts or extra virgin olive oil to a healthy diet on inflammatory markers in individuals with CAD.


Assuntos
Carya , Doença da Artéria Coronariana , Biomarcadores , Proteína C-Reativa , Dieta Saudável , Humanos , Interleucina-6 , Nozes , Azeite de Oliva
2.
Nutrition ; 91-92: 111411, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34425320

RESUMO

OBJECTIVE: The aim of this study was to determine the effects of a healthy diet supplemented with extra virgin olive oil or pecans on plasma fatty acids (PFAs) in patients with stable coronary artery disease (CAD). METHODS: Patients 40 to 80 y of age were randomized to one of three dietary interventions (allocation ratio 1: 1: 1): healthy diet based on guidelines (control group [CG]), healthy diet supplemented with 30 g/d of pecans (PNG), or a healthy diet supplemented with 30 mL/d of extra virgin olive oil (OOG). PFAs were identified at baseline and at the end of follow-up (12 wk), and correlations between dietary fatty acids intake, PFAs, and clinical biomarkers of the lipid profile were also assessed before and after the interventions. RESULTS: Among 149 participants included in the analysis (43 CG; 51 PNG; and 55 OOG), correlations were observed between food intake, PFAs, and lipid profile before and after interventions independent of statins used, but all were considered weak. At the end of the study, the OOG showed increased concentrations of oleic fatty acid independently of the type of statin in use (1.49%; 95% confidence interval, 0.08-2.89; P = 0.029); however, there were no significant differences between the groups regarding the final mean values of oleic fatty acid or in the other PFAs. CONCLUSIONS: In patients with stable CAD, there were no significant differences in PFAs after 12 wk according to dietary interventions evaluated.


Assuntos
Carya , Doença da Artéria Coronariana , Ácidos Graxos , Humanos , Ácido Oleico , Azeite de Oliva , Óleos de Plantas
3.
J Obes ; 2019: 3139278, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31354986

RESUMO

Background: Recruitment of monocytes and low-grade inflammation process are both involved in obesity and in atherosclerosis. Thus, the aim of this study was to evaluate the correlation among indicators of adiposity, monocyte subtypes, and inflammatory markers in patients with stable coronary artery disease (CAD). Methods: This was a cross-sectional study including 97 patients with stable CAD aged >40 years. Traditional anthropometric indicators of adiposity (body mass index (BMI); waist, hip, and neck circumferences; and waist-hip ratio) and nontraditional anthropometric indicators of adiposity (lipid accumulation product index (LAP), visceral adiposity index (VAI), and deep-abdominal-adipose-tissue index (DAAT)) were determined. Immunoprecipitation, turbidimetry, coagulometric method, and CBA were used for the evaluation of inflammatory markers (hs-CRP, IL-2, IL-4, IL-6, IL-10, and INF-γ). Monocyte subtypes were identified by flow cytometry and defined as CD14++ CD16- (Mon1), CD14++ CD16+ (Mon2), and CD14+ CD16++ (Mon3). Pearson's correlation coefficient and adjusted partial correlation were calculated. Results: Monocyte subtypes were correlated with inflammation regardless of nutritional status according to BMI. In overweight individuals, LAP was correlated with IL-4 and fibrinogen (P < 0.01 and P < 0.05, respectively) and VAI with IL-4 (P < 0.05). In obese patients, the BMI, waist, neck, and hip circumferences, and DAAT were correlated with IL-6 (P < 0.05), regardless of age and sex. The hip circumference was correlated positively with Mon1 (r = 0.40, P = 0.007) and negatively with Mon3 (r = -0.35, P = 0.02) in obese subjects. Conclusion: Monocyte subtypes are correlated with inflammation in patients with stable CAD independently of BMI, whereas traditional and nontraditional indicators of adiposity are correlated differently with inflammatory markers and monocytes, according to the nutritional status.


Assuntos
Doença da Artéria Coronariana/sangue , Inflamação/sangue , Monócitos/fisiologia , Obesidade/fisiopatologia , Adiposidade , Antropometria , Biomarcadores/sangue , Índice de Massa Corporal , Doença da Artéria Coronariana/fisiopatologia , Estudos Transversais , Feminino , Humanos , Inflamação/fisiopatologia , Masculino , Pessoa de Meia-Idade , Monócitos/classificação , Obesidade/sangue , Obesidade/complicações
4.
Nutr J ; 18(1): 5, 2019 01 19.
Artigo em Inglês | MEDLINE | ID: mdl-30660196

RESUMO

BACKGROUND: This study aimed to evaluate the effect of the intake of yerba mate (YM) and green tea (GT) on serum levels of leptin and paraoxonase-1 (PON-1), compared to control. METHODS: Controlled, randomized clinical trial (RCT) that evaluated 142 men and women affected by overweight or obesity aged 35-60 years, untreated dyslipidemia and no history of coronary artery disease. Participants were randomized to ingest 1000 mL GT, YM or apple tea (AT, control group) daily, during eight weeks. Serum PON-1 and leptin levels were analyzed by ELISA immunoassay at the beginning (baseline) and after eight weeks of intervention. RESULTS: The intake of 1 l of YM/day resulted in significant increase in serum levels of PON-1 (9.7%; p = 0.005). The consumption of GT induced no significant difference in the levels of PON-1 (p = 0.154) and leptin (p = 0.783). Intergroup analysis showed a significant difference (p = 0.036) in the variation of PON-1 levels in the YM group when compared to GT and AT groups. In addition, the increase in PON-1 levels in the YM group was significantly associated with increased HDL-c (p = 0.004). CONCLUSIONS: The intake of yerba mate increased the antioxidant capacity by increasing serum levels of PON-1 and was positively associated with increased HDL-c, stressing the protective role of this beverage against atherosclerotic diseases. GT intake had no significant effect on serum levels of PON-1 and leptin. TRIAL REGISTRATION: This study is registered with ClinicalTrials.gov under protocol number NCT00933647.


Assuntos
Arildialquilfosfatase/sangue , Dislipidemias/sangue , Ilex paraguariensis , Leptina/sangue , Sobrepeso/sangue , Chá , Adulto , Antioxidantes/análise , Bebidas , Índice de Massa Corporal , HDL-Colesterol/sangue , Feminino , Humanos , Ilex paraguariensis/química , Masculino , Pessoa de Meia-Idade , Obesidade/sangue , Fitoterapia , Extratos Vegetais/administração & dosagem
5.
Arq. bras. cardiol ; 111(6): 810-821, Dec. 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-973805

RESUMO

Abstract Background: Children with familial hypercholesterolemia may develop early endothelial damage leading to a high risk for the development of cardiovascular disease (CVD). Statins have been shown to be effective in lowering LDL cholesterol levels and cardiovascular events in adults. The effect of statin treatment in the pediatric population is not clearly demonstrated. Objective: To systematically review the literature to evaluate the effects of different statins and dosages in total cholesterol levels in children and adolescents with familial hypercholesterolemia. We also aimed to evaluate statin safety in this group. Methods: PubMed, EMBASE, Bireme, Web of Science, Cochrane Library, SciELO and LILACS databases, were searched for articles published from inception until February 2016. Two independent reviewers performed the quality assessment of the included studies. We performed a meta-analysis with random effects and inverse variance, and subgroup analyses were performed. Results: Ten trials involving a total of 1543 patients met the inclusion criteria. Our study showed reductions in cholesterol levels according to the intensity of statin doses (high, intermediate and low): (-104.61 mg/dl, -67.60 mg/dl, -56.96 mg/dl) and in the low-density lipoprotein cholesterol level: [-105.03 mg/dl (95% CI -115.76, -94.30), I2 19.2%], [-67.85 mg/dl (95% CI -83.36, -52.35), I2 99.8%], [-58.97 mg/dl (95% CI -67.83, -50.11), I2 93.8%. The duration of statin therapy in the studies ranged from 8 to 104 weeks, precluding conclusions about long-term effects. Conclusion: Statin treatment is efficient in lowering lipids in children with FH. There is need of large, long-term and randomized controlled trials to establish the long-term safety of statins.


Resumo Fundamentos: Crianças com hipercolesterolemia familiar podem desenvolver dano endotelial precoce, aumentando o risco de desenvolver doenças cardiovasculares. As estatinas tiveram sua eficácia em diminuir níveis de colesterol LDL e eventos cardiovasculares em adultos comprovada. O efeito das estatinas na população pediátrica não está claramente demonstrado. Objetivo: Revisar sistematicamente a literatura para avaliar os efeitos e a segurança de diferentes estatinas e suas dosagens nos níveis de colesterol total em crianças e adolescentes com hipercolesterolêmica familiar. Métodos: Artigos publicados desde o início até fevereiro de 2016 foram pesquisados nas bases PubMed, EMBASE, Bireme, Web of Science, Cochrane Library, SciELO e LILACS. Dois revisores independentes avaliaram a qualidade dos estudos incluídos. Realizamos meta-análise com efeitos aleatórios e variância inversa. Análises de subgrupos foram realizadas. Resultados: Dez ensaios envolvendo 1.543 pacientes preencheram os critérios de inclusão. Em nosso estudo, as análises demostraram reduções nos níveis de colesterol, de acordo com a intensidade das doses de estatina (alta, intermediária e baixa): (-104,61 mg/dl, -67,60 mg/dl, -56,96 mg/dl) e no nível de lipoproteínas de baixa densidade: [-105,03 mg/dl (IC95% -115.76, -94.30), I2 19.2%], [-67.85 mg/dl (IC95% -83.36, -52.35), I2 99.8%], [-58.97 mg/dl (IC95% -67.83, -50.11), I2 93,8%. A duração da terapia com estatina variou de 8 a 104 semanas, impedindo conclusões sobre os efeitos a longo prazo. Conclusão: O tratamento com estatinas é eficiente na redução de lipídios em crianças com hipercolesterolemia familiar. É necessário realizar ensaios controlados randomizados de longo prazo para estabelecer a segurança do uso de estatinas a longo prazo.


Assuntos
Humanos , Criança , Adolescente , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Hiperlipoproteinemia Tipo II/tratamento farmacológico , Anticolesterolemiantes/uso terapêutico , Fatores de Tempo , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do Tratamento , Inibidores de Hidroximetilglutaril-CoA Redutases/administração & dosagem , Relação Dose-Resposta a Droga , Hiperlipoproteinemia Tipo II/sangue , HDL-Colesterol/sangue , LDL-Colesterol/sangue , Anticolesterolemiantes/administração & dosagem
6.
Arq Bras Cardiol ; 111(6): 810-821, 2018 12.
Artigo em Inglês, Português | MEDLINE | ID: mdl-30365601

RESUMO

BACKGROUND: Children with familial hypercholesterolemia may develop early endothelial damage leading to a high risk for the development of cardiovascular disease (CVD). Statins have been shown to be effective in lowering LDL cholesterol levels and cardiovascular events in adults. The effect of statin treatment in the pediatric population is not clearly demonstrated. OBJECTIVE: To systematically review the literature to evaluate the effects of different statins and dosages in total cholesterol levels in children and adolescents with familial hypercholesterolemia. We also aimed to evaluate statin safety in this group. METHODS: PubMed, EMBASE, Bireme, Web of Science, Cochrane Library, SciELO and LILACS databases, were searched for articles published from inception until February 2016. Two independent reviewers performed the quality assessment of the included studies. We performed a meta-analysis with random effects and inverse variance, and subgroup analyses were performed. RESULTS: Ten trials involving a total of 1543 patients met the inclusion criteria. Our study showed reductions in cholesterol levels according to the intensity of statin doses (high, intermediate and low): (-104.61 mg/dl, -67.60 mg/dl, -56.96 mg/dl) and in the low-density lipoprotein cholesterol level: [-105.03 mg/dl (95% CI -115.76, -94.30), I2 19.2%], [-67.85 mg/dl (95% CI -83.36, -52.35), I2 99.8%], [-58.97 mg/dl (95% CI -67.83, -50.11), I2 93.8%. The duration of statin therapy in the studies ranged from 8 to 104 weeks, precluding conclusions about long-term effects. CONCLUSION: Statin treatment is efficient in lowering lipids in children with FH. There is need of large, long-term and randomized controlled trials to establish the long-term safety of statins.


Assuntos
Anticolesterolemiantes/uso terapêutico , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Hiperlipoproteinemia Tipo II/tratamento farmacológico , Adolescente , Anticolesterolemiantes/administração & dosagem , Criança , HDL-Colesterol/sangue , LDL-Colesterol/sangue , Relação Dose-Resposta a Droga , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/administração & dosagem , Hiperlipoproteinemia Tipo II/sangue , Ensaios Clínicos Controlados Aleatórios como Assunto , Fatores de Tempo , Resultado do Tratamento
7.
Arq Bras Cardiol ; 111(4): 618-625, 2018 Oct.
Artigo em Inglês, Português | MEDLINE | ID: mdl-30365684

RESUMO

Severe carotid atherosclerotic disease is responsible for 14% of all strokes, which result in a high rate of morbidity and mortality. In recent years, advances in clinical treatment of cardiovascular diseases have resulted in a significant decrease in mortality due to these causes. To review the main studies on carotid revascularization, evaluating the relationship between risks and benefits of this procedure. The data reviewed show that, for a net benefit, carotid intervention should only be performed in cases of a periprocedural risk of less than 6% in symptomatic patients. The medical therapy significantly reduced the revascularization net benefit ratio for stroke prevention in asymptomatic patients. Real life registries indicate that carotid stenting is associated with a greater periprocedural risk. The operator annual procedure volume and patient age has an important influence in the rate of stroke and death after carotid stenting. Symptomatic patients have a higher incidence of death and stroke after the procedure. Revascularization has the greatest benefit in the first weeks of the event. There is a discrepancy in the scientific literature about carotid revascularization and/or clinical treatment, both in primary and secondary prevention of patients with carotid artery injury. The identification of patients who will really benefit is a dynamic process subject to constant review.


Assuntos
Angioplastia/métodos , Estenose das Carótidas/cirurgia , Endarterectomia das Carótidas/métodos , Medição de Risco , Stents , Artérias Carótidas/cirurgia , Estenose das Carótidas/complicações , Humanos , Fatores de Risco , Acidente Vascular Cerebral/etiologia , Resultado do Tratamento
8.
Arq. bras. cardiol ; 111(4): 618-625, Oct. 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-973768

RESUMO

Abstract Severe carotid atherosclerotic disease is responsible for 14% of all strokes, which result in a high rate of morbidity and mortality. In recent years, advances in clinical treatment of cardiovascular diseases have resulted in a significant decrease in mortality due to these causes. To review the main studies on carotid revascularization, evaluating the relationship between risks and benefits of this procedure. The data reviewed show that, for a net benefit, carotid intervention should only be performed in cases of a periprocedural risk of less than 6% in symptomatic patients. The medical therapy significantly reduced the revascularization net benefit ratio for stroke prevention in asymptomatic patients. Real life registries indicate that carotid stenting is associated with a greater periprocedural risk. The operator annual procedure volume and patient age has an important influence in the rate of stroke and death after carotid stenting. Symptomatic patients have a higher incidence of death and stroke after the procedure. Revascularization has the greatest benefit in the first weeks of the event. There is a discrepancy in the scientific literature about carotid revascularization and/or clinical treatment, both in primary and secondary prevention of patients with carotid artery injury. The identification of patients who will really benefit is a dynamic process subject to constant review.


Resumo A doença aterosclerótica carotídea grave é responsável por 14% de todos os acidentes vasculares cerebrais (AVC), que refletem em uma alta taxa de morbimortalidade. Nos últimos anos, os avanços no tratamento clínico das doenças cardiovasculares geraram um decréscimo importante na mortalidade por estas causas. Revisar principais estudos que dizem respeito à revascularização carotídea avaliando a relação entre risco e beneficio deste procedimento. Os dados encontrados indicam que o procedimento só deve ser realizado se houver um risco periprocedimento menor que 6% em pacientes sintomáticos para que haja beneficio líquido na intervenção carotídea. O tratamento clínico reduziu significativamente o benefício líquido da revascularização na prevenção de AVC em pacientes assintomáticos. Registros que refletem a prática diária demonstram que a angioplastia carotídea esta associada a um risco periprocedimento mais elevado. O volume anual de procedimentos por operador e a idade dos pacientes têm uma importante influência nas taxas de AVC e morte pós angioplastia. Pacientes sintomáticos têm uma maior incidência de AVC e morte após procedimento. A revascularização tem o maior benefício nas primeiras semanas do evento. Existem discrepâncias na literatura científica com relação à revascularização carotídea e/ou tratamento clínico, tanto na prevenção primária quanto secundária de pacientes com lesão carotídea. A identificação do paciente que realmente será beneficiado é um processo dinâmico sujeito a constante revisão.


Assuntos
Humanos , Stents , Endarterectomia das Carótidas/métodos , Estenose das Carótidas/cirurgia , Angioplastia/métodos , Medição de Risco , Artérias Carótidas/cirurgia , Fatores de Risco , Resultado do Tratamento , Estenose das Carótidas/complicações , Acidente Vascular Cerebral/etiologia
9.
Arq Bras Cardiol ; 111(3): 356-361, 2018 Sep.
Artigo em Inglês, Português | MEDLINE | ID: mdl-30156604

RESUMO

BACKGROUND: Long-term safety, effectiveness and criteria for treatment with statins in children are still unclear in clinical practice. There is very limited evidence for the use of medication to treat children with dyslipidemia secondary to obesity who do not respond well to lifestyle modification. OBJECTIVE: Systematic review of randomized clinical trials of statin use to treat children and adolescents with dyslipidemia secondary to obesity. METHODS: We performed a search in PubMed, EMBASE, Bireme, Web of Science, Cochrane Library, SciELO, and LILACS for data to evaluate the effect of statins on: improvement of surrogate markers of coronary artery disease in clinical outcomes of adulthood; increased serum levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and apolipropotein B (APOB); and decreased serum levels of high-density lipoprotein cholesterol (HDL-C) from inception to February 2016. Participants were children and adolescents. RESULTS: Of the 16793 potentially relevant citations recovered from the electronic databases, no randomized clinical trials fulfilled the inclusion criteria for children with dyslipidemia secondary to obesity. CONCLUSIONS: We found no specific evidence to consider statins in the treatment of hypercholesterolemia secondary to obesity in children. The usual practice of extrapolating findings from studies in genetic dyslipidemia ignores the differences in long-term cardiovascular risks and the long-term drug treatment risks, when compared to recommendation of lifestyle changes. Randomized clinical trials are needed to understand drug treatment in dyslipidemia secondary to obesity.


Assuntos
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Hipercolesterolemia/tratamento farmacológico , Hipercolesterolemia/etiologia , Obesidade Infantil/complicações , Adolescente , Criança , Dislipidemias/tratamento farmacológico , Dislipidemias/etiologia , Humanos , Estilo de Vida , Ensaios Clínicos Controlados Aleatórios como Assunto , Fatores de Risco , Resultado do Tratamento
10.
Arq. bras. cardiol ; 109(6): 599-605, Dec. 2017. tab
Artigo em Inglês | LILACS | ID: biblio-887976

RESUMO

Abstract The best approach of multivessel coronary artery disease in the context of acute myocardial infarction with ST segment elevation and primary percutaneous coronary intervention is one of the main reasons for controversy in cardiology. Although the main global guidelines do not recommend routine complete revascularization in these patients, recent randomized clinical trials have demonstrated benefit of this approach in reducing cardiovascular outcomes. For this reason, an adequate review of this evidence is essential in order to establish scientifically based strategy and achieve better outcomes for these patients who present with acute myocardial infarction. This review aims to present objectively the most recent evidence available on this topic.


Resumo O adequado manejo da doença arterial coronariana (DAC) multivascular, no contexto do infarto agudo do miocárdio com supradesnivelamento do segmento ST e da intervenção coronariana percutânea primária, é um dos grandes motivos de controvérsia em Cardiologia. Embora as principais diretrizes mundiais não recomendem a revascularização completa de forma rotineira nesses pacientes, recentes ensaios clínicos randomizados (ECRs) têm demonstrado benefício dessa abordagem na redução de desfechos cardiovasculares. Por esse motivo, torna-se imprescindível uma adequada revisão dessas evidências, a fim de que se possa estabelecer uma conduta cientificamente embasada e capaz de trazer benefícios aos pacientes que se apresentam no contexto agudo do infarto do miocárdio. Esta revisão objetivou apresentar de forma objetiva as evidências mais recentes disponíveis a respeito desse tema.


Assuntos
Humanos , Doença da Artéria Coronariana/cirurgia , Intervenção Coronária Percutânea/métodos , Infarto do Miocárdio com Supradesnível do Segmento ST/cirurgia , Doença da Artéria Coronariana/mortalidade , Infarto do Miocárdio com Supradesnível do Segmento ST/mortalidade , Revascularização Miocárdica
11.
Arq Bras Cardiol ; 109(6): 599-605, 2017 Dec.
Artigo em Inglês, Português | MEDLINE | ID: mdl-29185617

RESUMO

The best approach of multivessel coronary artery disease in the context of acute myocardial infarction with ST segment elevation and primary percutaneous coronary intervention is one of the main reasons for controversy in cardiology. Although the main global guidelines do not recommend routine complete revascularization in these patients, recent randomized clinical trials have demonstrated benefit of this approach in reducing cardiovascular outcomes. For this reason, an adequate review of this evidence is essential in order to establish scientifically based strategy and achieve better outcomes for these patients who present with acute myocardial infarction. This review aims to present objectively the most recent evidence available on this topic.


Assuntos
Doença da Artéria Coronariana/cirurgia , Intervenção Coronária Percutânea/métodos , Infarto do Miocárdio com Supradesnível do Segmento ST/cirurgia , Doença da Artéria Coronariana/mortalidade , Humanos , Revascularização Miocárdica , Infarto do Miocárdio com Supradesnível do Segmento ST/mortalidade
12.
Nutrients ; 9(10)2017 Sep 30.
Artigo em Inglês | MEDLINE | ID: mdl-28973999

RESUMO

Coronary artery disease (CAD) is responsible for more than 7 million deaths worldwide. In the early stages of the development of atherosclerotic plaques, cardiovascular risk factors stimulate vascular endothelial cells, initiating an inflammatory process, fundamental in the pathogenesis of CAD. The inclusion of potentially cardioprotective foods, such as olive oil, to the diet, may aid in the control of these risk factors, and in the reduction of cytokines and inflammatory markers. The present review aims to address the interaction between phenolic compounds present in olive oil, and inflammation, in the prevention and treatment of CAD. In vitro and in vivo studies suggest that phenolic compounds, such as hydroxytyrosol, tyrosol, and their secoiridoid derivatives, may reduce the expression of adhesion molecules and consequent migration of immune cells, modify the signaling cascade and the transcription network (blocking the signal and expression of the nuclear factor kappa B), inhibit the action of enzymes responsible for the production of eicosanoids, and consequently, decrease circulating levels of inflammatory markers. Daily consumption of olive oil seems to modulate cytokines and inflammatory markers related to CAD in individuals at risk for cardiovascular diseases. However, clinical studies that have evaluated the effects of olive oil and its phenolic compounds on individuals with CAD are still scarce.


Assuntos
Doença das Coronárias/prevenção & controle , Azeite de Oliva/química , Fenóis/farmacologia , Humanos , Fenóis/química
13.
Trials ; 17(1): 437, 2016 09 05.
Artigo em Inglês | MEDLINE | ID: mdl-27596284

RESUMO

BACKGROUND: Cardiovascular disease has become a major health problem, and it has been associated with both environmental and genetic factors. Studies have shown that the Mediterranean Diet (MeDiet), or its components such as nuts and olive oil, may be strongly associated with the improvement of cardiovascular risk factors in specific populations. The purpose of the GENUTRI study is to investigate the interaction of genetics with cardiovascular risk factors in a non-Mediterranean population with coronary artery disease (CAD) according to three different diets: rich in pecan nuts, in extra-virgin olive oil or a control diet. METHODS/DESIGN: The GENUTRI study is a single-center, randomized, open-label, parallel-group, 12-week pragmatic clinical trial conducted in patients aged 40 to 80 years and diagnosed with CAD. A standardized questionnaire will be applied to data collection and a blood sample will be obtained for lipid, glycemic and inflammatory profile evaluation. Polymorphisms in the CD36 and STAT3 genes will be detected using the TaqMan® SNP Genotyping Assay. Patients will be allocated in three groups: group 1: 30 g/day of pecan nuts; group 2: 30 ml/day of olive oil; and group 3: control diet. The primary outcome will consist of changes in LDL-cholesterol (in mg/dl) after 12 weeks of intervention. DISCUSSION: Studies have shown the beneficial effects of diets rich in nuts and olive oil mainly in the Mediterranean population. GENUTRI is a clinical trial focusing on the effects of nuts or olive oil supplementation in Brazilian individuals. Additionally, we will try to demonstrate that genetic polymorphisms linked to cardiovascular disease may modulate the effects of different diets on biochemical and inflammatory markers among these subjects. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02202265 (registered on 18 July 2014: first version).


Assuntos
Antígenos CD36/genética , Doença da Artéria Coronariana/dietoterapia , Doença da Artéria Coronariana/genética , Dieta Mediterrânea , Polimorfismo de Nucleotídeo Único , Fator de Transcrição STAT3/genética , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/sangue , Glicemia/metabolismo , Brasil , Carya , LDL-Colesterol/sangue , Protocolos Clínicos , Doença da Artéria Coronariana/sangue , Doença da Artéria Coronariana/diagnóstico , Feminino , Interação Gene-Ambiente , Genótipo , Hemoglobinas Glicadas/metabolismo , Humanos , Mediadores da Inflamação/sangue , Insulina/sangue , Masculino , Pessoa de Meia-Idade , Nozes , Azeite de Oliva , Fenótipo , Projetos de Pesquisa , Fatores de Tempo , Resultado do Tratamento
14.
Arq. bras. cardiol ; 106(6): 457-463, tab, graf
Artigo em Inglês | LILACS | ID: lil-787317

RESUMO

Abstract Background: Excessive weight is a cardiovascular risk factor since it generates a chronic inflammatory process that aggravates the endothelial function. Objective: To evaluate the endothelial function in individuals with excess weight and mild dyslipidemia using brachial artery flow-mediated dilation (BAFMD), and the association of endothelial function with anthropometric and biochemical variables. Methods: Cross-sectional study that included 74 individuals and evaluated anthropometric variables (body mass index [BMI], waist-hip ratio [WHR], waist circumference [AC], and percentage of body fat [PBF]), biochemical (blood glucose, insulinemia, ultrasensitive C-reactive protein, fibrinogen, total cholesterol, HDL-cholesterol, triglycerides, and LDL-cholesterol) and endothelial function (BAFMD, evaluated by ultrasound). The statistical analysis was performed with SPSS, version 16.0. To study the association between the variables, we used chi-square, Student's t and Mann-Whitney tests, and Pearson's correlation. Logistic regression analyzed the independent influence of the factors. Values of p < 0.05 were considered significant. Results: The participants had a mean age of 50.8 years, and 57% were female. BMI, WC, WHR, and PBF showed no significant association with BAFMD. The male gender (p = 0.02) and higher serum levels of fibrinogen (p = 0.02) were significantly and independently associated with a BAFMD below 8%. Conclusions: In individuals with excess weight and mild untreated dyslipidemia, male gender and higher levels of fibrinogen were independently associated with worse BAFMD.


Resumo Fundamento: O excesso de peso é um fator de risco cardiovascular, pois gera um processo inflamatório crônico que agrava a função endotelial. Objetivo: Avaliar a função endotelial de indivíduos com excesso de peso e dislipidemia leve através da dilatação da artéria braquial mediada pelo fluxo (DABMF) e sua associação com variáveis antropométricas e bioquímicas. Métodos: Estudo transversal com inclusão de 74 indivíduos e avaliação de variáveis antropométricas (índice de massa corporal [IMC], razão cintura-quadril [RCQ], circunferência abdominal [CA] e percentual de gordura corporal [PGC]), bioquímicas (glicemia, insulinemia, proteína C reativa ultrassensível, fibrinogênio, colesterol total, HDL-colesterol, triglicerídeos e LDL-colesterol) e função endotelial (DABMF, avaliada por ultrassonografia). A análise estatística foi realizada pelo programa SPSS, versão 16.0. Para estudar a associação entre as variáveis, foram utilizados os testes do qui-quadrado, t de Student, Mann-Whitney e correlação de Pearson. Regressão logística analisou a influência independente dos fatores. Valores de p < 0,05 foram considerados significativos. Resultados: Os participantes tinham uma média de idade de 50,8 anos e 57% eram do gênero feminino. O IMC, a CA, a RCQ e o PGC não mostraram associação significativa com a DABMF. O gênero masculino (p = 0,02) e níveis séricos mais elevados de fibrinogênio (p = 0,02) estiveram significativamente e independentemente associados a uma DABMF inferior a 8%. Conclusões: Em indivíduos com excesso de peso e dislipidemia leve não tratada, o gênero masculino e níveis mais elevados de fibrinogênio foram associados de forma independente com uma pior DABMF.


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Fibrinogênio/análise , Endotélio Vascular/fisiopatologia , Aterosclerose/sangue , Dislipidemias/fisiopatologia , Sobrepeso/fisiopatologia , Fluxo Sanguíneo Regional/fisiologia , Peso Corporal , Artéria Braquial/fisiopatologia , Biomarcadores/sangue , Fatores Sexuais , Antropometria , Tecido Adiposo/fisiopatologia , Colesterol/sangue , Estudos Transversais , Fatores de Risco , Aterosclerose/etiologia , Dislipidemias/complicações , Sobrepeso/complicações
15.
Arq Bras Cardiol ; 106(6): 457-63, 2016 Jun.
Artigo em Inglês, Português | MEDLINE | ID: mdl-27142650

RESUMO

BACKGROUND: Excessive weight is a cardiovascular risk factor since it generates a chronic inflammatory process that aggravates the endothelial function. OBJECTIVE: To evaluate the endothelial function in individuals with excess weight and mild dyslipidemia using brachial artery flow-mediated dilation (BAFMD), and the association of endothelial function with anthropometric and biochemical variables. METHODS: Cross-sectional study that included 74 individuals and evaluated anthropometric variables (body mass index [BMI], waist-hip ratio [WHR], waist circumference [AC], and percentage of body fat [PBF]), biochemical (blood glucose, insulinemia, ultrasensitive C-reactive protein, fibrinogen, total cholesterol, HDL-cholesterol, triglycerides, and LDL-cholesterol) and endothelial function (BAFMD, evaluated by ultrasound). The statistical analysis was performed with SPSS, version 16.0. To study the association between the variables, we used chi-square, Student's t and Mann-Whitney tests, and Pearson's correlation. Logistic regression analyzed the independent influence of the factors. Values of p < 0.05 were considered significant. RESULTS: The participants had a mean age of 50.8 years, and 57% were female. BMI, WC, WHR, and PBF showed no significant association with BAFMD. The male gender (p = 0.02) and higher serum levels of fibrinogen (p = 0.02) were significantly and independently associated with a BAFMD below 8%. CONCLUSIONS: In individuals with excess weight and mild untreated dyslipidemia, male gender and higher levels of fibrinogen were independently associated with worse BAFMD.


Assuntos
Aterosclerose/sangue , Dislipidemias/fisiopatologia , Endotélio Vascular/fisiopatologia , Fibrinogênio/análise , Sobrepeso/fisiopatologia , Tecido Adiposo/fisiopatologia , Adulto , Antropometria , Aterosclerose/etiologia , Biomarcadores/sangue , Peso Corporal , Artéria Braquial/fisiopatologia , Colesterol/sangue , Estudos Transversais , Dislipidemias/complicações , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Sobrepeso/complicações , Fluxo Sanguíneo Regional/fisiologia , Fatores de Risco , Fatores Sexuais
16.
Arq. bras. cardiol ; 105(6): 573-579, Dec. 2015. tab
Artigo em Português | LILACS | ID: lil-769533

RESUMO

Abstract Background: Due to the importance of coronary artery disease (CAD), continuous investigation of the risk factors (RFs) is needed. Objective: To evaluate the prevalence of RFs for CAD in cities in Rio Grande do Sul State, and compare it with that reported in a similar study conducted in the same cities in 2002. Methods: Cross-sectional study on 1,056 healthy adults, investigating the prevalence and absolute and relative frequencies of the following RFs for CAD: obesity, systemic arterial hypertension (SAH), dyslipidemias, smoking, sedentary lifestyle, diabetes mellitus, and family history, as well as age and sex. Data was collected in 19 cities, host of the Offices of the Regional Coordinators of Health, as in the 2002 study. Results: Twenty-six percent of the sample consisted of older adults and 57% were women. The prevalence of sedentary lifestyle was 44%, history family 50%, smoking 23%, overweight/obesity 68%, dyslipidemia (high cholesterol levels) 43%, SAH 40%, and diabetes 11%. When compared to the 2002 study, the prevalence of active smoking and sedentary behavior decreased, whereas the prevalence of hypertension, dyslipidemia and obesity increased. Obesity is the most prevalent RF in women, and SAH the most prevalent in men. Conclusions: The prevalence of RFs for CAD in Rio Grande do Sul State remains high. Hypertension, obesity and dyslipidemia are still prevalent and require major prevention programs. Smoking and physical inactivity have decreased in the state, suggesting the efficacy of related campaigns.


Resumo Fundamento: Diante da importância da doença arterial coronariana (DAC), é necessário pesquisar continuamente seus fatores de risco (FR). Objetivo: Conhecer a prevalência dos FR da DAC em cidades do Estado do Rio Grande do Sul (RS), e compará-la com a encontrada em pesquisa semelhante realizada nas mesmas cidades em 2002. Métodos: Estudo transversal de uma amostra de 1056 indivíduos adultos, em que se pesquisou a prevalência e frequências absolutas e relativas dos seguintes FR para a DAC: obesidade, hipertensão arterial sistêmica (HAS), dislipidemias, tabagismo, sedentarismo, diabetes mellitus, e antecedentes familiares de cardiopatia isquêmica, além de idade e gênero. A coleta de dados foi realizada em 19 cidades sede das Coordenadorias Regionais de Saúde do RS, como feito em 2002. Resultados: A amostra foi constituída de 26% de idosos e 57% de mulheres. As prevalências dos FR foram de 44% de sedentarismo, 50% de antecedentes familiares, 23% de tabagismo, 68% de sobrepeso/obesidade, 43% de dislipidemia (colesterol elevado), 40% de HAS, e 11% de diabetes. Quando comparado ao estudo de 2002, verificou-se que a população de fumantes ativos e sedentários diminuiu, e a de hipertensos, dislipidêmicos e obesos aumentou. A obesidade é o FR mais prevalente em mulheres, e a HAS o mais prevalente em homens. Conclusão: A prevalência dos FR da DAC no RS continua alta. Fatores como hipertensão, obesidade, dislipidemia continuam elevados e demandam maiores programas de prevenção. O hábito de fumar e a inatividade física têm diminuído no estado, sugerindo a eficácia das campanhas relacionadas.


Assuntos
Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Doença da Artéria Coronariana/etiologia , Diabetes Mellitus/epidemiologia , Dislipidemias/epidemiologia , Hipertensão/epidemiologia , Obesidade/epidemiologia , Fumar/epidemiologia , Fatores Etários , Brasil/epidemiologia , Estudos Transversais , Doença da Artéria Coronariana/epidemiologia , Complicações do Diabetes , Dislipidemias/complicações , Hipertensão/complicações , Obesidade/complicações , Prevalência , Fatores de Risco , Comportamento Sedentário , Fatores Sexuais , Fumar/efeitos adversos
17.
Rev Assoc Med Bras (1992) ; 61(5): 458-68, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26603010

RESUMO

INTRODUCTION: several studies have evaluated the utilization of lipid biomarkers in an attempt to correlate them with clinical cardiovascular events. Nevertheless, the investigation of clinical conditions under specific plasmatic levels of lipoproteins for long periods presents limitations due to inherent difficulties that are related to the follow-up of individuals throughout their lives. Better understanding of the clinical response and occasional resistance to the action of hypolipidemic drugs in several clinic scenarios is also necessary. OBJECTIVES: to determine the role of evaluation of single-nucleotide polymorphisms (SNPs) related to the metabolism of lipids, and its implications in different clinical scenarios. METHODS: a search of the literature in English and Spanish languages was performed in Medline, Lilacs via Bireme, IBECS via Bireme, and Cochrane databases. The expected results included information regarding plasmatic lipid profile and SNPs, cardiovascular clinical outcomes and polymorphisms related to the effectiveness of statins in the treatment of hypercholesterolemia. RESULTS: in order to perform this analysis, 19 studies were included from a total of 89 identified citations. The evaluation of the results suggests that low plasmatic levels of LDL-c are associated with a reduction in the risk of heart attacks, although this was not observed for the rise of plasmatic levels of HDL-c. CONCLUSION: polymorphisms in different populations and clinical perspectives may bring important contributions for a better understanding and adequacy of plasmatic lipoproteins aiming at reducing cardiovascular risk.


Assuntos
Doenças Cardiovasculares/prevenção & controle , Dislipidemias/sangue , Metabolismo dos Lipídeos/fisiologia , Polimorfismo de Nucleotídeo Único/fisiologia , Doenças Cardiovasculares/sangue , LDL-Colesterol/sangue , LDL-Colesterol/efeitos dos fármacos , Dislipidemias/metabolismo , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Metabolismo dos Lipídeos/efeitos dos fármacos , Polimorfismo de Nucleotídeo Único/efeitos dos fármacos
18.
Rev. Assoc. Med. Bras. (1992) ; 61(5): 458-468, Sept.-Oct. 2015. tab, graf
Artigo em Inglês | LILACS | ID: lil-766255

RESUMO

Summary Introduction: several studies have evaluated the utilization of lipid biomarkers in an attempt to correlate them with clinical cardiovascular events. Nevertheless, the investigation of clinical conditions under specific plasmatic levels of lipoproteins for long periods presents limitations due to inherent difficulties that are related to the follow-up of individuals throughout their lives. Better understanding of the clinical response and occasional resistance to the action of hypolipidemic drugs in several clinic scenarios is also necessary. Objectives: to determine the role of evaluation of single-nucleotide polymorphisms (SNPs) related to the metabolism of lipids, and its implications in different clinical scenarios. Methods: a search of the literature in English and Spanish languages was performed in Medline, Lilacs via Bireme, IBECS via Bireme, and Cochrane databases. The expected results included information regarding plasmatic lipid profile and SNPs, cardiovascular clinical outcomes and polymorphisms related to the effectiveness of statins in the treatment of hypercholesterolemia. Results: in order to perform this analysis, 19 studies were included from a total of 89 identified citations. The evaluation of the results suggests that low plasmatic levels of LDL-c are associated with a reduction in the risk of heart attacks, although this was not observed for the rise of plasmatic levels of HDL-c. Conclusion: polymorphisms in different populations and clinical perspectives may bring important contributions for a better understanding and adequacy of plasmatic lipoproteins aiming at reducing cardiovascular risk.


Resumo Introdução: muitos estudos tem avaliado a utilização de biomarcadores lipídicos na tentativa de correlacioná-los com eventos clínicos cardiovasculares. Contudo, a investigação de condições clínicas sob níveis plasmáticos específicos de lipoproteínas por longos períodos, apresenta limitações devido às dificuldades inerentes relacionadas ao acompanhamento de indivíduos ao longo de suas vidas. Adicionalmente, há a necessidade de melhor compreensão da resposta clínica e eventual resistência da ação de drogas hipolipemiantes em diversos cenários clínicos. Objetivos: determinar o papel da avaliação de polimorfismos de nucleotídeo único (SNPs) relacionadas com o metabolismo lipídico e suas implicações em diferentes cenários clínicos. Métodos: foi realizada uma pesquisa na literatura de língua inglesa e espanhola nas bases de dados Medline, Lilacas via Bireme, IBECS via Bireme e Cochrane. Os resultados esperados incluíam informações sobre o perfil lipídico plasmático e SNPs, desfechos clínicos cardiovasculares e polimorfismos relacionadas à efetividade de estatinas quanto ao tratamento da hipercolesterolemia. Resultados: para esta análise foram incluídos 19 estudos de um total de 89 citações identificadas. Os dados resultantes e avaliados sugerem que baixos níveis plasmáticos de LDL-c estão associados com redução do risco de infarto do miocárdio o que não foi observado para o aumento nos níveis plasmáticos de HDL-c. Conclusão: os polimorfismos em diferentes populações e perspectivas clínicas podem trazer importantes contribuições para a melhor compreensão e adequação de metas de lipoproteínas plasmáticas que visem a redução de risco cardiovascular.


Assuntos
Humanos , Doenças Cardiovasculares/prevenção & controle , Dislipidemias/sangue , Metabolismo dos Lipídeos/fisiologia , Polimorfismo de Nucleotídeo Único/fisiologia , Doenças Cardiovasculares/sangue , LDL-Colesterol/sangue , LDL-Colesterol/efeitos dos fármacos , Dislipidemias/metabolismo , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Metabolismo dos Lipídeos/efeitos dos fármacos , Polimorfismo de Nucleotídeo Único/efeitos dos fármacos
19.
Rev Assoc Med Bras (1992) ; 61(1): 72-80, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25909213

RESUMO

OBJECTIVES: the conditions of obesity and overweight pose a major risk for a number of comorbidities, including clinical syndromes resulting from atherosclerotic disease. Recent studies strongly indicate that adipose tissue is an active endocrine organ that secretes bioactive factors such as adipokines. Adiponectin appears to have a regulatory role in the mechanism of insulin resistance and in the development of atherosclerosis. This systematic review aims to evaluate the anti-atherogenic effects of adiponectin and its properties to improve and mimic metabolic and vascular actions of insulin and its influence on endothelial function. METHODS: a qualitative, exploratory and literature review was performed in the PubMed, Portal Capes and Scielo databases using as key-words "adiponectin", "obesity", "insulin resistance", "anti-inflammatory", "therapeutic strategies" and "future prospects". RESULTS: evidence suggests that adiponectin has anti-atherogenic properties with anti-inflammatory effects on the vascular wall. Moreover, it modifies the vascular intracellular signaling and has indirect antioxidant effects on the human myocardium. On the other hand, there are studies suggesting that increased levels of adiponectin are paradoxically associated with a worse prognosis in heart failure syndrome, although the mechanisms are not clear. CONCLUSION: it is not clear whether adiponectin levels have any clinical significance for risk stratification in cardiovascular disease or if they simply reflect the activation of complex underlying mechanisms. Changes in lifestyle and some drug treatments for hypertension and coronary heart disease have shown significant effect to increase adiponectin levels, and simultaneously decrease in insulin resistance and endothelial dysfunction.


Assuntos
Adiponectina/fisiologia , Tecido Adiposo/metabolismo , Resistência à Insulina/fisiologia , Obesidade/metabolismo , Adiponectina/biossíntese , Doenças Cardiovasculares/metabolismo , Feminino , Humanos , Estilo de Vida , Masculino , Obesidade/complicações , Receptores de Adiponectina/metabolismo , Fatores de Risco
20.
Rev. Assoc. Med. Bras. (1992) ; 61(1): 72-80, Jan-Feb/2015. graf
Artigo em Inglês | LILACS | ID: lil-744720

RESUMO

Objectives: the conditions of obesity and overweight pose a major risk for a number of comorbidities, including clinical syndromes resulting from atherosclerotic disease. Recent studies strongly indicate that adipose tissue is an active endocrine organ that secretes bioactive factors such as adipokines. Adiponectin appears to have a regulatory role in the mechanism of insulin resistance and in the development of atherosclerosis. This systematic review aims to evaluate the anti-atherogenic effects of adiponectin and its properties to improve and mimic metabolic and vascular actions of insulin and its influence on endothelial function. Methods: a qualitative, exploratory and literature review was performed in the PubMed, Portal Capes and Scielo databases using as key-words "adiponectin", "obesity", "insulin resistance", "anti-inflammatory", "therapeutic strategies" and "future prospects". Results: evidence suggests that adiponectin has anti-atherogenic properties with anti-inflammatory effects on the vascular wall. Moreover, it modifies the vascular intracellular signaling and has indirect antioxidant effects on the human myocardium. On the other hand, there are studies suggesting that increased levels of adiponectin are paradoxically associated with a worse prognosis in heart failure syndrome, although the mechanisms are not clear. Conclusion: it is not clear whether adiponectin levels have any clinical significance for risk stratification in cardiovascular disease or if they simply reflect the activation of complex underlying mechanisms. Changes in lifestyle and some drug treatments for hypertension and coronary heart disease have shown significant effect to increase adiponectin levels, and simultaneously decrease in insulin resistance and endothelial dysfunction. .


Objetivos: as condições de obesidade e sobrepeso representam um grande risco para uma série de comorbidades, incluindo as síndromes clínicas decorrentes da doença aterosclerótica. Recentes estudos indicam fortemente que o tecido adiposo é um órgão endócrino ativo que secreta fatores bioativos, como as adipocinas. A adiponectina parece ter um papel regulador no mecanismo da resistência à insulina e no desenvolvimento da aterosclerose. Este estudo de revisão tem como objetivo avaliar os efeitos antiaterogênicos da adiponectina e suas propriedades para melhorar e reproduzir ações metabólicas e vasculares de insulina e sua influência na função endotelial. Métodos: revisão qualitativa, exploratória e bibliográfica foi realizada nas bases de dados PubMed, Portal Capes e Scielo utilizando os unitermos "adiponectin", "obesity", "insulin resistance", "anti-inflammatory", "therapeutic strategies" e "future prospects". Resultados: evidências sugerem que a adiponectina tem propriedades antiaterogênicas com efeitos anti-inflamatórios sobre a parede vascular. Além disso, modifica a sinalização vascular intracelular e exerce efeitos antioxidantes indiretos sobre o miocárdio humano. Por outro lado, existem estudos que sugerem que níveis aumentados de adiponectina são paradoxalmente associados com pior prognóstico na síndrome de insuficiência cardíaca, embora os mecanismos ainda não estejam claros. Conclusão: é incerto se os níveis de adiponectina têm algum significado clínico para a estratificação de risco na doença cardiovascular ou se simplesmente refletem a ativação dos mecanismos complexos subjacentes. Modificações de estilo de vida e alguns tratamentos medicamentosos para hipertensão e doenças coronarianas têm tido efeitos importantes para aumentar os níveis de adiponectina e, simultaneamente, diminuir a resistência à insulina e a disfunção endotelial. .


Assuntos
Feminino , Humanos , Masculino , Adiponectina/fisiologia , Tecido Adiposo/metabolismo , Resistência à Insulina/fisiologia , Obesidade/metabolismo , Adiponectina/biossíntese , Doenças Cardiovasculares/metabolismo , Estilo de Vida , Obesidade/complicações , Fatores de Risco , Receptores de Adiponectina/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...